In small-molecule drug discovery, the value of a molecular building block depends not only on whether its structure is novel, but also on whether it can be effectively introduced into target molecules and provide well-defined variables for structural optimization.
The anticancer drug Lenalidomide was once one of the world's top-selling small molecule drugs and orphan drugs, with sales of up to 9.978 billion US dollars in 2022, and its development company Celgene made huge profits.
Small-molecule drugs are variable-specificity drugs targeted within cells, typically well-defined organic substances with a molecular weight of fewer than 900 Daltons, that help regulate biological processes. Due to differences in size, manufacturing, pharmacokinetics, pharmacodynamics, and ...